Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599833 | 1.00 | MEN1 (0.46) | MEN1KMT2AKDM4EALDH1A1PDE4D | |
| SCHEMBL2150013 | 0.85 | ALDH1A1 (0.44) | MEN1KMT2AKDM4EALDH1A1PDE4D | |
| SCHEMBL3596581 | 0.85 | ALDH1A1 (0.44) | MEN1KMT2AKDM4EALDH1A1PDE4D | |
| SCHEMBL2149214 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2AKDM4EALDH1A1TP53 | |
| SCHEMBL3595123 | 0.84 | ALDH1A1 (0.40) | MEN1KMT2AKDM4EALDH1A1TP53 | |
| SCHEMBL15527872 | 0.79 | TP53 (0.57) | MEN1KMT2AALDH1A1PDE4DHDAC1 | |
| SCHEMBL3599836 | 0.78 | HDAC1 (0.47) | MEN1KMT2AKDM4EALDH1A1PDE4D | |
| SCHEMBL28799137 | 0.78 | KDM4E (0.49) | MEN1KMT2AKDM4EALDH1A1TP53 | |
| SCHEMBL16810695 | 0.75 | MEN1 (0.49) | MEN1KMT2AKDM4EALDH1A1TP53 | |
| SCHEMBL14930494 | 0.73 | PTGS2 (0.54) | MEN1KMT2AKDM4EALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562913-B1 | SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALOVIRUSES | AICURIS GMBH & CO KG (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-1562913-B1 | SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALOVIRUSES | AICURIS GMBH & CO KG (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-7709491-B2 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709491-B2 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709491-B2 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20060235032-A1 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | AIC246 AG & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
| EP-1562913-A1 | SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALOVIRUSES | Bayer HealthCare AG (DE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004041790-A1 | SUBSTITUTED QUINAZOLINES AS ANTIVIRAL AGENTS, ESPECIALLY AGAINST CYTOMEGALOVIRUSES | BAYER HEALTHCARE AG (DE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235032-A1 | Substituted quinazolines as antiviral agents, especially against cytomegaloviruses | TPMT, EIF2AK2, IRF3 | MEN1 1290/4885KMT2A 2130/4885KDM4E 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.